ADMA BIOLOGICS INC (ADMA) Fundamental Analysis & Valuation

NASDAQ:ADMA • US0008991046

Current stock price

10.6 USD
-0.3 (-2.75%)
At close:
10.64 USD
+0.04 (+0.38%)
After Hours:

This ADMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ADMA Profitability Analysis

1.1 Basic Checks

  • ADMA had positive earnings in the past year.
  • ADMA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ADMA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • ADMA's Return On Assets of 23.54% is amongst the best of the industry. ADMA outperforms 96.31% of its industry peers.
  • With an excellent Return On Equity value of 30.78%, ADMA belongs to the best of the industry, outperforming 96.50% of the companies in the same industry.
  • ADMA has a Return On Invested Capital of 27.76%. This is amongst the best in the industry. ADMA outperforms 98.83% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ADMA is significantly below the industry average of 28.06%.
  • The 3 year average ROIC (20.20%) for ADMA is below the current ROIC(27.76%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 28.80%, ADMA belongs to the top of the industry, outperforming 93.98% of the companies in the same industry.
  • The Operating Margin of ADMA (37.52%) is better than 96.70% of its industry peers.
  • The Gross Margin of ADMA (57.39%) is better than 75.92% of its industry peers.
  • ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ADMA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
  • Compared to 1 year ago, ADMA has more shares outstanding
  • ADMA has more shares outstanding than it did 5 years ago.
  • ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ADMA has an Altman-Z score of 12.54. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • ADMA's Altman-Z score of 12.54 is amongst the best of the industry. ADMA outperforms 84.08% of its industry peers.
  • ADMA has a debt to FCF ratio of 2.62. This is a good value and a sign of high solvency as ADMA would need 2.62 years to pay back of all of its debts.
  • ADMA's Debt to FCF ratio of 2.62 is amongst the best of the industry. ADMA outperforms 93.20% of its industry peers.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.15, ADMA is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 12.54
ROIC/WACC2.88
WACC9.64%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • ADMA has a Current Ratio of 6.71. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.71, ADMA is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
  • ADMA has a Quick Ratio of 3.74. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ADMA (3.74) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADMA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 20.00% over the past year.
  • The Revenue has grown by 19.63% in the past year. This is quite good.
  • ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.62% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.88% yearly.
  • ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.04% yearly.
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y33.88%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.04%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

8

4. ADMA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.67, the valuation of ADMA can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.98% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.54, ADMA is valued a bit cheaper.
  • ADMA is valuated reasonably with a Price/Forward Earnings ratio of 10.88.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 98.06% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, ADMA is valued a bit cheaper.
Industry RankSector Rank
PE 17.67
Fwd PE 10.88
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.95% of the companies listed in the same industry.
  • ADMA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ADMA is cheaper than 90.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 91.78
EV/EBITDA 12.57
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ADMA may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 40.03% in the coming years.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y43.82%
EPS Next 3Y40.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMA Dividend Analysis

5.1 Amount

  • No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA Fundamentals: All Metrics, Ratios and Statistics

ADMA BIOLOGICS INC

NASDAQ:ADMA (4/29/2026, 8:00:00 PM)

After market: 10.64 +0.04 (+0.38%)

10.6

-0.3 (-2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)02-25
Earnings (Next)05-13
Inst Owners93.43%
Inst Owner Change-0.14%
Ins Owners2.43%
Ins Owner Change1.18%
Market Cap2.52B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts80
Price Target23.97 (126.13%)
Short Float %8.44%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)-8.44%
PT rev (3m)-8.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.63%
EPS NY rev (1m)5.52%
EPS NY rev (3m)6.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 17.67
Fwd PE 10.88
P/S 4.95
P/FCF 91.78
P/OCF 50.09
P/B 5.29
P/tB 5.34
EV/EBITDA 12.57
EPS(TTM)0.6
EY5.66%
EPS(NY)0.97
Fwd EY9.19%
FCF(TTM)0.12
FCFY1.09%
OCF(TTM)0.21
OCFY2%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.28
PEG (5Y)N/A
Graham Number5.2016 (-50.93%)
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 12.54
F-Score6
WACC9.64%
ROIC/WACC2.88
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y33.88%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.04%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.51%
EBIT Next 3Y44.53%
EBIT Next 5Y33.81%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA Fundamental Analysis FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status for ADMA stock?

ChartMill assigns a valuation rating of 8 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


Can you provide the profitability details for ADMA BIOLOGICS INC?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the valuation of ADMA BIOLOGICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 17.67 and the Price/Book (PB) ratio is 5.29.


How financially healthy is ADMA BIOLOGICS INC?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.